Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia

Gregory W. Hosier; Naji J. Touma

首页> 外文期刊>Canadian Urological Association Journal >Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia

【24h】

Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia

机译：慢性淋巴细胞白血病患者对肾细胞癌对依鲁替尼（一种布鲁顿酪氨酸激酶抑制剂）的反应

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Canadian Urological Association Journal》 |2017年第5期|共3页
作者
Gregory W. Hosier; Naji J. Touma;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献
中文文献
专利

1. Ibrutinib: A novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia [J] . BarrientosJ., RaiK. Leukemia and lymphoma . 2013,第8期

机译：依鲁替尼：一种新型的布鲁顿酪氨酸激酶抑制剂，在慢性淋巴细胞性白血病患者中反应出色
2. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia [J] . Brown Jennifer R., Barrientos Jacqueline C., Barr Paul M., Blood: The Journal of the American Society of Hematology . 2015,第19期

机译：Bruton酪氨酸激酶抑制剂依鲁替尼联合化学免疫疗法治疗慢性淋巴细胞性白血病
3. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia [J] . Brown Jennifer R., Barrientos Jacqueline C., Barr Paul M., Blood: The Journal of the American Society of Hematology . 2015,第19期

机译：Bruton酪氨酸激酶抑制剂依鲁替尼联合化学免疫疗法治疗慢性淋巴细胞性白血病
4. Proteomics-based target deconvolution of clinical multi-kinase inhibitors inducing apoptosis in primary chronic lymphocytic leukemia cells (CLL) [C] . Marcus Bantscheff, Ulrich Kruse, Christian P. Pallasch, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2010

机译：基于蛋白质组学的临床多激酶抑制剂诱导肾凋亡凋亡的靶碎屑（CLL）
5. Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315. [D] . Liu, Ta-Ming. 2014

机译：激酶靶向疗法在慢性淋巴细胞性白血病中：获得性依鲁替尼耐药性的机制和OSU-T315的临床前开发。
6. Response of renal cell carcinoma to ibrutinib a bruton tyrosine kinase inhibitor in a patient treated for chronic lymphocytic leukemia [O] . Gregory W. Hosier, Naji J. Touma 2017

机译：慢性淋巴细胞白血病患者对肾细胞癌对依鲁替尼（一种布鲁顿酪氨酸激酶抑制剂）的反应
7. Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia [O] . Gregory W. Hosier, Naji J. Touma 2017

机译：肾细胞癌对慢性淋巴细胞白血病治疗的患者中肾细胞癌对伊布洛替尼的抗原酪氨酸激酶抑制剂

Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia

著录项

相似文献

相关主题

期刊订阅